Business
Physiomics Awarded New Contract by Numab
Physiomics plc has secured a new contract with Numab Therapeutics AG to develop a pharmacokinetic-pharmacodynamic (PK/PD) model for a key asset in Numab's Immunology and Inflammation pipeline. This collaboration aims to accelerate therapeutic development by informing the Target Candidate Profile and supporting early-stage, data-driven decision-making, with completion anticipated in the second quarter of 2026. Disclaimer*
About this update from Physiomics Plc
[{"type":"text","content":"\n\n28 January 2026\n \nPhysiomics plc\n(\"Physiomics\" or the \"Company\")\n \nPhysiomics Awarded New Contract by Numab Therapeutics\n \nPhysiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its valued and long-standing client, Numab Therapeutics AG (\"Numab Therapeutics\").\nThis project reflects the continued application of Physiomics' modelling expertise across Numab Therapeutics' pipeline to accelerate the development of innovative therapies, building further on the already well-established relationship.\nNumab Therapeutics is a biopharmaceutical company focused on the discovery and development of next-generation multispecific antibody-based therapeutics for inflammation and oncology. Under this new contract, Physiomics will develop a pharmacokinetic-pharmacodynamic (PK/PD) model to inform the Target Candidate Profile of a key asset in Numab Therapeutics' Immunology and Inflammation pipeline. The modelling work is intended to support data-driven decision-making at an early stage of development and is expected to commence imminently, with completion anticipated within Q2 2026.\nDr Peter Sargent, CEO of Physiomics, commented:\n\"We are delighted to continue our collaboration with Numab Therapeutics and to have the opportunity to contribute further insights across its promising pipeline. In particular, this work allows us to support earlier research and development decisions through quantitative, data-driven approaches, helping to shape candidate profiles at a critical stage and thus streamlining drug development journeys.\"\nFor more information about Physiomics and its services, please visit www.physiomics.co.uk.\n \nEnquiries:\n \nPhysiomics plc\nDr Peter Sargent, CEO\n+44 (0)1235 841575\n \nHybridan LLP (Broker)\nClaire Louise Noyce\n+44 (0) 203 764 2341\n \nStrand Hanson Ltd (NOMAD)\nJames Dance & James Bellman\n+44 (0)20 7409 3494\n \n \nNotes to Editor\n \nAbout Physiomics\n \nPhysiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug devel...